At the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda, integration with the wider healthcare system was widely presented as a practical response to ...

New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th ...

The risk of infection following a needlestick injury is very low. There have been no definite cases of HIV infection among healthcare workers following an occupational needlestick injury in the UK ...

Having an undetectable viral load means that there is not enough of the virus in body fluids to pass on HIV during sex. This is sometimes referred to as 'U=U'.

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the ...

Doxycycline post-exposure prophylaxis (doxyPEP), which was found to be highly effective at preventing sexually transmitted infections (STIs) among gay men and transgender women, did not protect young ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

Once again, a life expectancy study has shown that HIV-positive people who start antiretroviral therapy (ART) promptly and have good access to medical care live as long as their HIV-negative peers.

A prospective study that recruited a significant proportion of people newly diagnosed with HIV in four locations in Indonesia and offered them immediate antiretroviral therapy (ART) found that only 35 ...

Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been ...

In people who acquire HIV despite taking injectable cabotegravir as PrEP, the course of infection is quite distinct to that seen in people who aren’t taking PrEP, Professor Susan Eshleman of Johns ...